Pfizer Corporation

Rinat Neuroscience Corporation

Bristol-myers Squibb Compnay

Pavel Strop

Arvind Rajpal

David L Shelton

Russell Dushin

Magdalena Grazyna Dorywalska

Javier Fernando Chaparro Riggers

Weihsien Ho

Jaume Pons

Shu-Hui Liu

Wei-Hsien Ho

Thomas John Van Blarcom

Tracy Chia-Chien Kuo

Wei Chen

Yik Andy Yeung

Leila Marie Boustany

Edward Derrick Pascua

Chakrapani Subramanyam

Edmund Graziani

Christopher John O'Donnell

Andreas Maderna

Matthew David Doroski

Paul O Sheppard

Alan J Korman

Haichun Huang

Mohan Srinivasan

Guodong Chen

Richard Y Huang

Yasmina Noubia Abdiche

Robert F Graziano

Dangshe Ma

Kimberly Ann Marquette

Lawrence Nathan Tumey

Chetana Rao-Naik

Wenwu Zhai

Michelle Renee Kuhne

Hong Liang

Xiayang Qiu

Puja Sapra

Julie Jia Li Hawkins

Bruce Charles Gomes

Omar Khaled Ahmad

Xiaodi Deng

Olafur S Gudmundsson

Amy Shaw-Ru Chen

Thomas-Toan Tran

Beth C Vetelino

Davide Foletti

Meritxell Galindo Casas

Santiago Esteban Farias

David Shelton

David Louis Shelton

Natalie Bezman

Yuli Wang

Sujiet Puthenveetil

Kenneth John Dirico

Ludivine Moine

Gary Frederick Filzen

Stephen Paul Brown

Frank Loganzo, Jr

Sayumi Yamazoe

Patrick G Holder

Katherine Anne Delaria

Peter Sung Keun Lee

Gamze Ozlem Camdere

Lee Mary Beth Shaughnessy

Yiming Yin

Jacob Eli Gunn Glanville

Davide Luciano Foletti

Russell George Dushin

Edmund Idris Graziani

Beth Cooper Vetelino

Pradyot Nandi

Magdalena Dorywalska

Julie Jia Hawkins

Christopher John O'donnell

An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses

The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.

Calicheamicin derivatives and antibody drug conjugates thereof

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Therapeutic antibodies and their uses

The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.

Antibody-drug conjugates with high drug loading

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.

Heterodimeric proteins and methods for producing and purifying them

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.

Antibodies specific for Trop-2 and their uses

The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.

Stability-modulating linkers for use with antibody drug conjugates

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

Engineered polypeptide conjugates and methods for making thereof using transglutaminase

The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.

Engineered polypeptide conjugates using transglutaminase

The present invention provides site specific HER2 antibody drug conjugates and methods for preparing and using the same.

Site specific HER2 antibody drug conjugates

Growing community of inventors

San Mateo, CA, United States of America

Pavel Strop